Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in Elderly Patients With Secondary or High-risk AML
NCT04230239Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- Dec 2019
- Primary completion
- Apr 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), sponsored by Fundación PETHEMA. Started Dec 2019; status: completed.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04230239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230239.